Condition

Tumor, Solid

ClinicalTrials.gov condition label

Clinical trials10
Recruiting3
Common interventions17
Lead sponsors shown9

Clinical trials

10 shown
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid TumorNCT07433283 · 2024-11-12
RECRUITING
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsNCT06090266 · 2023-10-24
RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.NCT06022029 · 2023-10-13
RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerNCT05620134 · 2022-10-17
ACTIVE_NOT_RECRUITING
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)NCT05103358 · 2022-03-10
COMPLETED
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsNCT05082610 · 2022-02-28
COMPLETED
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsNCT05094804 · 2021-09-09
UNKNOWN
Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)NCT04788147 · 2021-03-26
COMPLETED
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsNCT03911557 · 2019-06-08
COMPLETED
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsNCT05974410
AVAILABLE

Trial status mix

COMPLETED4
RECRUITING3
ACTIVE_NOT_RECRUITING1
AVAILABLE1
UNKNOWN1

Phase mix

PHASE16
PHASE26
NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.